CareBright

Belkins
CareBright is a long established Irish home care provider. Our focus is caring for and supporting people to live independently in their own homes. We have been providing services to the community since 1998 .We are a service provider for the HSE, in the form of Home Care Grants, Home Help Services, Chiropody, and Subsidised Hours in the home, while also providing care for clients in a private capacity.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

EMERGENT BIOSOLUTIONS SELECTS AXIOM FUSION ECLINICAL SUITE AS ITS GLOBAL ECLINICAL SUITE

BioSpace | March 04, 2020

news image

Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services is pleased to announce its engagement with Emergent BioSolutions, Inc. (NYSE: EBS), a global life sciences company whose mission is to protect and enhance life by providing specialty products and contract development and manufacturing services that address public health threats....

Read More

INDUSTRIAL IMPACT

BIOLIFE SOLUTIONS CLOSES ACQUISITION OF SEXTON BIOTECHNOLOGIES

BioLife Solutions, Inc. | September 06, 2021

news image

BioLife Solutions, Inc., a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has closed its acquisition of Sexton Biotechnologies. Sexton's bioproduction tools portfolio includes proprietary closed vials for cell therapy final dose packaging, human platelet lysate (HPL) media, a bio-defined replacement for fetal bovine serum or human serum used in cell manuf...

Read More

CELL AND GENE THERAPY

PDS BIOTECH REPORTS AN INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

PDS Biotechnology Corporation | December 27, 2021

news image

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, announced that the compensation committee of the board of directors of the Company approved, on December 20, 2021, an equity award to Michael Lalond, the Company’s new Director of Quality Assurance, as a material inducement to Mr. Lalond entering into employment with PDS ...

Read More

MEDICAL

MODERNA ANNOUNCES SUPPLY AGREEMENT WITH UK GOVERNMENT FOR ADDITIONAL 2 MILLION DOSES OF MRNA-1273, MODERNA’S VACCINE CANDIDATE AGAINST COVID-19

Moderna | November 30, 2020

news image

Moderna, Inc., a biotechnology organization pioneering messenger RNA (mRNA) therapeutics and vaccines to make new generation of transformative medicines for patients, today reported a supply agreement with the UK government for an extra 2 million doses of mRNA-1273, Moderna's vaccine candidate against COVID-19, to the United Kingdom starting in March 2021. The UK government has now made sure about 7 million dosages of mRNA-1273. This confirmation comes as the UK proceeds with its efforts to ...

Read More
news image

EMERGENT BIOSOLUTIONS SELECTS AXIOM FUSION ECLINICAL SUITE AS ITS GLOBAL ECLINICAL SUITE

BioSpace | March 04, 2020

Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services is pleased to announce its engagement with Emergent BioSolutions, Inc. (NYSE: EBS), a global life sciences company whose mission is to protect and enhance life by providing specialty products and contract development and manufacturing services that address public health threats....

Read More
news image

INDUSTRIAL IMPACT

BIOLIFE SOLUTIONS CLOSES ACQUISITION OF SEXTON BIOTECHNOLOGIES

BioLife Solutions, Inc. | September 06, 2021

BioLife Solutions, Inc., a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has closed its acquisition of Sexton Biotechnologies. Sexton's bioproduction tools portfolio includes proprietary closed vials for cell therapy final dose packaging, human platelet lysate (HPL) media, a bio-defined replacement for fetal bovine serum or human serum used in cell manuf...

Read More
news image

CELL AND GENE THERAPY

PDS BIOTECH REPORTS AN INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

PDS Biotechnology Corporation | December 27, 2021

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, announced that the compensation committee of the board of directors of the Company approved, on December 20, 2021, an equity award to Michael Lalond, the Company’s new Director of Quality Assurance, as a material inducement to Mr. Lalond entering into employment with PDS ...

Read More
news image

MEDICAL

MODERNA ANNOUNCES SUPPLY AGREEMENT WITH UK GOVERNMENT FOR ADDITIONAL 2 MILLION DOSES OF MRNA-1273, MODERNA’S VACCINE CANDIDATE AGAINST COVID-19

Moderna | November 30, 2020

Moderna, Inc., a biotechnology organization pioneering messenger RNA (mRNA) therapeutics and vaccines to make new generation of transformative medicines for patients, today reported a supply agreement with the UK government for an extra 2 million doses of mRNA-1273, Moderna's vaccine candidate against COVID-19, to the United Kingdom starting in March 2021. The UK government has now made sure about 7 million dosages of mRNA-1273. This confirmation comes as the UK proceeds with its efforts to ...

Read More